{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:55:01Z","timestamp":1777956901940,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T00:00:00Z","timestamp":1322784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00347-011-2457-z","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T06:12:54Z","timestamp":1322806374000},"page":"45-53","source":"Crossref","is-referenced-by-count":4,"title":["Essenzieller Blepharospasmus","Essential blepharospasm"],"prefix":"10.1007","volume":"109","author":[{"given":"B.","family":"Wabbels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Roggenk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,2]]},"reference":[{"key":"2457_CR1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/mds.20020","volume":"19","author":"Atassi","year":"2004","unstructured":"Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19(Suppl 8):68\u201384","journal-title":"Mov Disord"},{"key":"2457_CR2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","volume":"15","author":"Bentivoglio","year":"2009","unstructured":"Bentivoglio AR, Fasano A, Ialongo T et al (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15:224\u2013231","journal-title":"Neurotox Res"},{"key":"2457_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.iop.0000217703.80859.a3","volume":"22","author":"Borodic","year":"2006","unstructured":"Borodic G (2006) Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 22:239\u2013240","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2457_CR4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J et al (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"2457_CR5","unstructured":"Ceballos-Baumann AO (1996) Dystonien. In: Conrad B, Ceballos-Baumann AO (Hrsg) Bewegungsst\u00f6rungen in der Neurologie. Thieme, Stuttgart"},{"key":"2457_CR6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1212\/WNL.0b013e3181c7da09","volume":"74","author":"Chinnapongse","year":"2010","unstructured":"Chinnapongse R, Lew MF, Pagan F et al (2010) A 7-year open-label safety and immunogenicity study of Myobloc in patients with cerviacal dystonia. Neurology 74:86\u201387","journal-title":"Neurology"},{"key":"2457_CR7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s004150070100","volume":"247","author":"Dressler","year":"2000","unstructured":"Dressler D (2000) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247:809\u2013810","journal-title":"J Neurol"},{"key":"2457_CR8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","volume":"48","author":"Dressler","year":"2002","unstructured":"Dressler D (2002) Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 48:26\u201329","journal-title":"Eur Neurol"},{"key":"2457_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00415-004-0347-x","volume":"251","author":"Dressler","year":"2004","unstructured":"Dressler D (2004) New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 251:360","journal-title":"J Neurol"},{"key":"2457_CR10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","volume":"252","author":"Dressler","year":"2005","unstructured":"Dressler D, Bigalke H (2005) Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 252:904\u2013907","journal-title":"J Neurol"},{"key":"2457_CR11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"Frevert","year":"2010","unstructured":"Frevert J (2010) Content of botulinum neurotoxin in botox(r)\/vistabel(r), dysport(r)\/azzalure(r), and xeomin(r)\/bocouture(r). Drugs R D 10:67\u201373","journal-title":"Drugs R D"},{"key":"2457_CR12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"Goschel","year":"1997","unstructured":"Goschel H, Wohlfarth K, Frevert J et al (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies \u2013 therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"2457_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217","journal-title":"Mov Disord"},{"key":"2457_CR14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004150070094","volume":"247","author":"Group","year":"2000","unstructured":"Group ESoDiEC (2000) A prevalence study of primary dystonia in eight european countries. J Neurol 247:787\u2013792","journal-title":"J Neurol"},{"key":"2457_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archopht.124.1.116","volume":"124","author":"Hall","year":"2006","unstructured":"Hall TA, McGwin G Jr, Searcey K et al (2006) Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 124:116\u2013119","journal-title":"Arch Ophthalmol"},{"key":"2457_CR16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.46.5.1213","volume":"46","author":"Hallett","year":"1996","unstructured":"Hallett M, Daroff RB (1996) Blepharospasm: report of a workshop. Neurology 46:1213\u20131218","journal-title":"Neurology"},{"key":"2457_CR17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1212\/01.wnl.0000327601.46315.85","volume":"71","author":"Hallett","year":"2008","unstructured":"Hallett M, Evinger C, Jankovic J, Stacy M (2008) Update on blepharospasm: report from the BEBRF International Workshop. Neurology 71:1275\u20131282","journal-title":"Neurology"},{"key":"2457_CR18","doi-asserted-by":"crossref","unstructured":"Jankovic J, Comella C, Hanschmann A, Grafe S (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial. Mov Disord 15;308(1\u20132):103\u2013109","DOI":"10.1002\/mds.23658"},{"key":"2457_CR19","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743\u20131746","journal-title":"Neurology"},{"key":"2457_CR20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186\u20131188","journal-title":"Neurology"},{"key":"2457_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/PL00007813","volume":"248","author":"Jost","year":"2001","unstructured":"Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl 1):21\u201324","journal-title":"J Neurol"},{"key":"2457_CR22","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","volume":"151","author":"Lee","year":"2005","unstructured":"Lee JC, Yokota K, Arimitsu H et al (2005) Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16\u00a0S toxin-haemagglutinin. Microbiology 151:3739\u20133747","journal-title":"Microbiology"},{"key":"2457_CR23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","volume":"116","author":"Muller","year":"2009","unstructured":"Muller K, Mix E, Adib Saberi F et al (2009) Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 116:579\u2013585","journal-title":"J Neural Transm"},{"key":"2457_CR24","first-page":"363","volume":"4","author":"Nussgens","year":"1995","unstructured":"Nussgens Z, Roggenkamper P (1995) Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol 4:363\u2013367","journal-title":"Ger J Ophthalmol"},{"key":"2457_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clineuro.2008.09.023","volume":"111","author":"Pekmezovic","year":"2009","unstructured":"Pekmezovic T, Svetel M, Ivanovic N et al (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161\u2013164","journal-title":"Clin Neurol Neurosurg"},{"key":"2457_CR26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/mds.10209","volume":"17","author":"Racette","year":"2002","unstructured":"Racette BA, Stambuk M, Perlmutter JS (2002) Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). Mov Disord 17:1098\u20131100","journal-title":"Mov Disord"},{"key":"2457_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0028-1090183","volume":"36","author":"Reichel","year":"2009","unstructured":"Reichel G, Stenner A, Hermann W (2009) Palpebrale Variante des Blepharospasmus \u2013 Abgrenzung zur Lid\u00f6ffnungsapraxie und zur Inhibitionsst\u00f6rung durch synchrone EMG-Ableitungen. Akt Neurol 36:60\u201364","journal-title":"Akt Neurol"},{"key":"2457_CR28","unstructured":"Roggenkaemper P, Laskawi R (2004) Essenzieller Blepharospasmus. In: Laskawi R, Roggenkaemper P (Hrsg) Botulinumtoxin-Therapie im Kopf-Hals-Bereich, 2.\u00a0Aufl. Urban & Vogel, M\u00fcnchen, S\u00a073\u201389"},{"key":"2457_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new Botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312","journal-title":"J Neural Transm"},{"key":"2457_CR30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","volume":"15","author":"Schulte-Baukloh","year":"2008","unstructured":"Schulte-Baukloh H, Bigalke H, Miller K et al (2008) Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 15:407\u2013415, discussion 415","journal-title":"Int J Urol"},{"key":"2457_CR31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9394(03)00075-8","volume":"136","author":"Snir","year":"2003","unstructured":"Snir M, Weinberger D, Bourla D et al (2003) Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 136:99\u2013105","journal-title":"Am J Ophthalmol"},{"key":"2457_CR32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A et al (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118(2):233\u2013239","journal-title":"J Neural Transm"},{"key":"2457_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00417-006-0392-5","volume":"245","author":"Wabbels","year":"2007","unstructured":"Wabbels B, Roggenkamper P (2007) Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy. Graefes Arch Clin Exp Ophthalmol 245:45\u201350","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2457-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-011-2457-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-011-2457-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T05:16:02Z","timestamp":1561007762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-011-2457-z"}},"subtitle":["Praxisnahe Therapie mit Botulinumtoxin unter Verwendung verk\u00fcrzter Behandlungsintervalle","Practice-oriented therapy with botulinum toxin employing reduced treatment intervals"],"short-title":[],"issued":{"date-parts":[[2011,12,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["2457"],"URL":"https:\/\/doi.org\/10.1007\/s00347-011-2457-z","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,2]]}}}